Please Wait.....
Report
NA Acute LymphocyticLymphoblastic Leukemia (ALL) Diagnostics Market
Market Report I 2022-12-01 I 229 Pages I Data Bridge Market Research
The North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) diagnostics market is projected to register a substantial CAGR of 7.6% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2023 to 2030
Market Segmentation:
North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market, By Product Type (Instruments and Consumables & Accessories), Test Type (Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (B-cell Lymphoblastic Leukemia/Lymphoma, and T-cell Lymphoblastic Leukemia), Age Group (Below 21, 21-29, 30-65, 65 and Above), Gender (Male and Female) End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) diagnostics market are:
- Rise in prevalence and incidence of leukemia cancer
- Increase in healthcare expenditure for cancer diagnosis and treatment
Market Players:
Some of the major players operating in the North America Acute Lymphocytic/Lymphoblastic Leukemia (ALL) diagnostics market are:
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific, Inc.
- QIAGEN
- Abbott
- Siemens Medical Solutions USA, Inc.
- Merck KGaA
- Hologic, Inc.
- bioMerieux SA
- Agilent Technologies, Inc.
- DiaSorin S.p.A.
- Illumina, Inc.
- Myriad Genetics, Inc.
- Quest Diagnostics Incorporated.
- Bio-Rad Laboratories, Inc.
- Koninklijke Philips N.V.
- BD
- Exact Sciences Corporation
- Time Medical Holding
- Michelson Diagnostics Ltd.
- MinFound Medical Systems Co., Ltd
TABLE OF CONTENTS
1 INTRODUCTION 54
1.1 OBJECTIVES OF THE STUDY 54
1.2 MARKET DEFINITION 54
1.3 OVERVIEW OF NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET 54
1.4 LIMITATIONS 56
1.5 MARKETS COVERED 57
2 MARKET SEGMENTATION 60
2.1 MARKETS COVERED 60
2.2 GEOGRAPHICAL SCOPE 61
2.3 YEARS CONSIDERED FOR THE STUDY 62
2.4 CURRENCY AND PRICING 62
2.5 DBMR TRIPOD DATA VALIDATION MODEL 63
2.6 MULTIVARIATE MODELLING 66
2.7 PRODUCT TYPE LIFELINE CURVE 66
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 67
2.9 DBMR MARKET POSITION GRID 68
2.10 MARKET TESTING TYPE COVERAGE GRID 70
2.11 VENDOR SHARE ANALYSIS 71
2.12 SECONDARY SOURCES 72
2.13 ASSUMPTIONS 72
3 EXECUTIVE SUMMARY 73
4 PREMIUM INSIGHTS 76
4.1 PESTEL ANALYSIS 77
4.2 PORTER'S FIVE FORCES 78
4.3 INDUSTRY INSIGHTS 79
5 EPIDEMIOLOGY 81
6 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, REGULATIONS 82
7 MARKET OVERVIEW 85
7.1 DRIVERS 87
7.1.1 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS 87
7.1.2 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 87
7.1.3 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER 88
7.1.4 GROWING PREVALENCE OF LEUKEMIA CANCER 88
7.2 RESTRAINTS 90
7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS 90
7.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA 91
7.3 OPPORTUNITIES 91
7.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA 91
7.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 92
7.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 92
7.4 CHALLENGES 93
7.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 93
7.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 94
8 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY PRODUCT TYPE 95
8.1 OVERVIEW 96
8.2 INSTRUMENTS 99
8.2.1 BIOPSY INSTRUMENTS 100
8.2.1.1 BONE MARROW BIOPSY 100
8.2.1.2 NEEDLE BIOPSY 100
8.2.1.3 SURGEON BIOPSY 101
8.2.1.4 OTHERS 101
8.2.2 PATHOLOGY-BASED INSTRUMENTS 101
8.2.2.1 PCR INSTRUMENTS 101
8.2.2.2 SLIDE STAINING SYSTEMS 101
8.2.2.3 TISSUE PROCESSING SYSTEMS 101
8.2.2.4 CELL PROCESSORS 102
8.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS 102
8.2.3 IMAGING INSTRUMENTS 102
8.2.3.1 ULTRASOUND SYSTEMS 102
8.2.3.2 CT SYSTEMS 102
8.2.3.3 MRI SYSTEMS 102
8.2.3.4 OTHERS 103
8.2.4 OTHERS 103
8.3 CONSUMABLES & ACCESSORIES 103
8.3.1 KITS 104
8.3.1.1 PCR KITS 104
8.3.1.2 DNA POLYMERASE KITS 104
8.3.1.3 NUCLEIC ACID ISOLATION KITS 104
8.3.1.4 OTHERS 105
8.3.2 REAGENTS 105
8.3.2.1 ASSAYS 105
8.3.2.2 BUFFERS 105
8.3.2.3 PRIMERS 105
8.3.2.4 OTHERS 105
8.3.3 PROBES 106
8.3.4 OTHER CONSUMABLES 106
9 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY TEST TYPE 107
9.1 OVERVIEW 108
9.2 BIOPSY 111
9.2.1 BONE MARROW BIOPSY 112
9.2.2 NEEDLE BIOPSY 112
9.2.3 SURGEON BIOPSY 112
9.2.4 OTHERS 112
9.3 BLOOD TEST 113
9.3.1 BLOOD CHEMISTRY TESTS 114
9.3.2 COMPLETE BLOOD COUNT (CBC) 114
9.3.3 OTHERS 114
9.4 IMAGING TEST 114
9.4.1 COMPUTED TOMOGRAPHY (CT) SCAN 115
9.4.2 MRI 115
9.4.3 POSITRON EMISSION TOMOHRAPHY (PET) SCAN 116
9.4.4 OTHERS 116
9.5 OTHERS 116
10 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY CANCER TYPE 117
10.1 OVERVIEW 118
10.2 B-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA 121
10.2.1 EARLY PRE-B ALL 122
10.2.2 COMMON ALL 122
10.2.3 PRE-B ALL 122
10.2.4 MATURE B-CELL ALL 122
10.3 T-CELL LYMPHOBLASTIC LEUKEMIA 122
10.3.1 PRE-T ALL 123
10.3.2 MATURE T-CELL ALL 123
11 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY AGE GROUP 124
11.1 OVERVIEW 125
11.2 BELOW 21 128
11.3 21-29 129
11.4 30-65 130
11.5 65 AND ABOVE 131
12 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY GENDER 132
12.1 OVERVIEW 133
12.2 MALE 136
12.3 FEMALE 137
13 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY END USER 138
13.1 OVERVIEW 139
13.2 HOSPITALS 142
13.3 ASSOCIATED LABS 142
13.4 INDEPENDENT DIAGNOSTIC LABORATORIES 143
13.5 DIAGNOSTIC IMAGING CENTERS 144
13.6 CANCER RESEARCH INSTITUTES 144
13.7 OTHERS 145
14 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 146
14.1 OVERVIEW 147
14.2 DIRECT TENDER 150
14.3 RETAIL SALES 151
15 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, BY REGION 152
15.1 NORTH AMERICA 153
15.1.1 U.S. 165
15.1.2 CANADA 171
15.1.3 MEXICO 177
16 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET, COMPANY LANDSCAPE 183
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 183
17 SWOT ANALYSIS 184
18 NORTH AMERICA ACUTE LYMPHOCYTIC/LYMPHOBLASTIC LEUKEMIA (ALL) DIAGNOSTICS MARKET 185
18.1 F. HOFFMANN-LA ROCHE LTD. 185
18.1.1 COMPANY SNAPSHOT 185
18.1.2 REVENUE ANALYSIS 185
18.1.3 COMPANY SHARE ANALYSIS 186
18.1.4 PRODUCT PORTFOLIO 186
18.1.5 RECENT DEVELOPMENT 186
18.2 THERMO FISHER SCIENTIFIC INC. 187
18.2.1 COMPANY SNAPSHOT 187
18.2.2 REVENUE ANALYSIS 187
18.2.3 COMPANY SHARE ANALYSIS 188
18.2.4 PRODUCT PORTFOLIO 188
18.2.5 RECENT DEVELOPMENT 188
18.3 QIAGEN 189
18.3.1 COMPANY SNAPSHOT 189
18.3.2 REVENUE ANALYSIS 189
18.3.3 COMPANY SHARE ANALYSIS 190
18.3.4 PRODUCT PORTFOLIO 190
18.3.5 RECENT DEVELOPMENT 190
18.4 ABBOTT 191
18.4.1 COMPANY SNAPSHOT 191
18.4.2 REVENUE ANALYSIS 191
18.4.3 COMPANY SHARE ANALYSIS 192
18.4.4 PRODUCT PORTFOLIO 192
18.4.5 RECENT DEVELOPMENT 192
18.5 SIEMENS MEDICAL SOLUTIONS USA, INC. 193
18.5.1 COMPANY SNAPSHOT 193
18.5.2 REVENUE ANALYSIS 193
18.5.3 COMPANY SHARE ANALYSIS 194
18.5.4 PRODUCT PORTFOLIO 194
18.5.5 RECENT DEVELOPMENT 194
18.6 MERCK KGAA 195
18.6.1 COMPANY SNAPSHOT 195
18.6.2 REVENUE ANALYSIS 195
18.6.3 PRODUCT PORTFOLIO 196
18.6.4 RECENT DEVELOPMENT 196
18.7 HOLOGIC INC. 197
18.7.1 COMPANY SNAPSHOT 197
18.7.2 REVENUE ANALYSIS 197
18.7.3 PRODUCT PORTFOLIO 198
18.7.4 RECENT DEVELOPMENT 198
18.8 AGILENT TECHNOLOGIES, INC. 199
18.8.1 COMPANY SNAPSHOT 199
18.8.2 REVENUE ANALYSIS 199
18.8.3 PRODUCT PORTFOLIO 200
18.8.4 RECENT DEVELOPMENT 200
18.9 BD 201
18.9.1 COMPANY SNAPSHOT 201
18.9.2 REVENUE ANALYSIS 201
18.9.3 PRODUCT PORTFOLIO 202
18.9.4 RECENT DEVELOPMENT 202
18.10 BIOMERIEUX SA 203
18.10.1 COMPANY SNAPSHOT 203
18.10.2 REVENUE ANALYSIS 203
18.10.3 PRODUCT PORTFOLIO 204
18.10.4 RECENT DEVELOPMENTS 204
18.11 BIO-RAD LABORATORIES, INC. 205
18.11.1 COMPANY SNAPSHOT 205
18.11.2 REVENUE ANALYSIS 205
18.11.3 PRODUCT PORTFOLIO 206
18.11.4 RECENT DEVELOPMENT 206
18.12 DIASORIN S.P.A. 207
18.12.1 COMPANY SNAPSHOT 207
18.12.2 REVENUE ANALYSIS 207
18.12.3 PRODUCT PORTFOLIO 208
18.12.4 RECENT DEVELOPMENTS 208
18.13 EXACT SCIENCE CORPORATION 209
18.13.1 COMPANY SNAPSHOT 209
18.13.2 REVENUE ANALYSIS 209
18.13.3 PRODUCT PORTFOLIO 210
18.13.4 RECENT DEVELOPMENT 210
18.14 ILLUMINA, INC. 211
18.14.1 COMPANY SNAPSHOT 211
18.14.2 REVENUE ANALYSIS 211
18.14.3 PRODUCT PORTFOLIO 212
18.14.4 RECENT DEVELOPMENT 212
18.15 KONINKLIJKE PHILIPS N.V. 213
18.15.1 COMPANY SNAPSHOT 213
18.15.2 REVENUE ANALYSIS 213
18.15.3 PRODUCT PORTFOLIO 214
18.15.4 RECENT DEVELOPMENT 214
18.16 MEDONICA CO. LTD 215
18.16.1 COMPANY SNAPSHOT 215
18.16.2 PRODUCT PORTFOLIO 215
18.16.3 RECENT DEVELOPMENT 215
18.17 MICHAEL DIAGNOSTICS LTD 216
18.17.1 COMPANY SNAPSHOT 216
18.17.2 PRODUCT PORTFOLIO 216
18.17.3 RECENT DEVELOPMENT 216
18.18 MINFOUND MEDICAL SYSTEMS CO., LTD 217
18.18.1 COMPANY SNAPSHOT 217
18.18.2 PRODUCT PORTFOLIO 217
18.18.3 RECENT DEVELOPMENT 217
18.19 MYRIAD GENETICS, INC. 218
18.19.1 COMPANY SNAPSHOT 218
18.19.2 REVENUE ANALYSIS 218
18.19.3 PRODUCT PORTFOLIO 219
18.19.4 RECENT DEVELOPMENT 219
18.20 PLEXBIO 220
18.20.1 COMPANY SNAPSHOT 220
18.20.2 PRODUCT PORTFOLIO 220
18.20.3 RECENT DEVELOPMENTS 220
18.21 QUEST DIAGNOSTICS INCORPORATED 221
18.21.1 COMPANY SNAPSHOT 221
18.21.2 REVENUE ANALYSIS 221
18.21.3 PRODUCT PORTFOLIO 222
18.21.4 RECENT DEVELOPMENTS 222
18.22 STERNMED GMBH 223
18.22.1 COMPANY SNAPSHOT 223
18.22.2 PRODUCT PORTFOLIO 223
18.22.3 RECENT DEVELOPMENTS 223
18.23 TIME MEDICAL HOLDING 224
18.23.1 COMPANY SNAPSHOT 224
18.23.2 PRODUCT PORTFOLIO 224
18.23.3 RECENT DEVELOPMENT 224
19 QUESTIONNAIRE 225
20 RELATED REPORTS 229
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security